The significant binding affinity of Apelin across various receptors like AT1R, β1AR, IL-6R, and VEGFR2, as evidenced by its lowest ΔGbinding values in both MM/PBSA calculations and MD simulations, further cements its potential as a leading therapeutic peptide for CAD. Here, APLN is linked to coronary artery disorder.